Pyxis Oncology PYXS
NASDAQ PYXS
$1.68 -0.03 (-1.46%)
As of: Oct 23, 2026 · 1:59 PM EDT

Pyxis Oncology (PYXS) Return on Sales [ROS] (2024 - 2026)

Updated

Pyxis Oncology (PYXS) recorded Return on Sales [ROS] of -631.38% in Q2 2026, up 68.98 percentage points from -700.35% a year earlier.

Analysis

Pyxis Oncology (PYXS) Return on Sales [ROS] (2024 - 2026) Analysis & Trends

For FY2025, Pyxis Oncology reported Return on Sales [ROS] of -609.18%, down 55.11 percentage points from FY2024.

  • Across earlier years, Return on Sales [ROS] came in at -554.07% in FY2024.
  • Quarterly Return on Sales [ROS] has ranged from -3765.74% in Q3 2025 to -34.71% in Q1 2024 over the past five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,132.13 Bn 1,100.72 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 634.87 Bn 554.73 Bn 17.30 Bn 24.35%
3 AbbVie 506.59 Bn 479.70 Bn 12.70 Bn 37.86%
4 Merck 357.59 Bn 311.97 Bn 12.21 Bn -3.52%
5 Novartis Ag 291.51 Bn 255.50 Bn 11.24 Bn 32.97%
6 Astrazeneca 265.00 Bn 238.69 Bn 12.86 Bn 20.57%
7 Amgen 238.17 Bn 193.57 Bn 7.24 Bn 34.95%
8 Gilead Sciences 195.18 Bn 169.37 Bn 6.22 Bn -133.21%
9 Pfizer 171.20 Bn 117.84 Bn 10.94 Bn 28.37%
10 Pyxis Oncology 107.83 Mn -157.23 Mn - -631.38%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -631.38%
Dec 31, 2025 -165.75%
Sep 30, 2025 -3,765.74%
Jun 30, 2025 -700.35%
Dec 31, 2024 -554.07%
Mar 31, 2024 -34.71%
API Access

Pyxis Oncology Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=PYXS&period=max&api_key=YOUR_API_KEY